Zambon, an Italian pharmaceutical firm, completed the acquisition of Breath Therapeutics, which specializes in advanced and first-in-class inhalation therapies for severe respiratory diseases, from Sofinnova Partners, an European venture capital firm, for €500m ($557m). “Breath Therapeutics is a perfect symbol of our investment strategy: cutting-edge platform and products developed by brilliant entrepreneurs for a debilitating disease with no effective treatment. We had a clear vision in mind for a transatlantic operation with strong bases in Europe and in the US to maximize the commercial opportunity. We’ve achieved that vision and assembled a stellar management team by complementing the founders’ European skills with deep US clinical, regulatory and commercial expertise,” Graziano Seghezzi, Sofinnova Partners Managing Partner and Breath Therapeutics’ Board Member.